source · text/markdown
source_14aa497b978a48e9
sha256 c2c19e9219f24d746e03de0b751ccc2c7af625022a9edf7ba663fbe757e1ad58
by researka:v2 · 2026-06-29 05:57:41.946049+04:00
# Hypothesis-Generating Brief: SGLT2 inhibitor — full paper ## Abstract Evidence-honesty note: 10/12 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on SGLT2 inhibitor across 12 included source papers and 692 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 10 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 21 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the safety outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, cardiometabolic, safety and comorbidity, and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that SGLT2 inhibitor should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. ## Introduction Aging populations are reshaping the clinical priorities of internal medicine and cardiology alike, and the question of whether drugs already in widespread use can extend healthspan — the years a person spends free of chronic-disease disability — has moved from speculative to operational. SGLT2 inhibitors sit at the intersection of two converging pressures: a demographic transition in which multimorbid adults now live long enough to accumulate heart failure, chronic kidney disease, and frailty, and a regulatory environment that has, over the past decade, granted these agents expanding labels across diabetes, heart failure, and renal disease. The question of whether SGLT2 inhibitors meaningfully slow aging biology — rather than simply attenuate single-organ decline — is no longer hypothetical, because mechanistic and real-world signals continue to accumulate faster than the trial apparatus can test them. Frailty is itself a powerful adverse prognostic marker in cardiovascular and renal medicine, with gait-speed thresholds near 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) widely used to stratify risk, and grip-strength cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) anchoring sarcopenia diagnosis. The field therefore needs to know whether SGLT2 inhibitors do anything to the trajectory underlying these markers, not only to the discrete events used in registrational trials. Why this question matters now is that a single mechanistic reframing could change prescribing for tens of millions of adults, making the evidentiary stakes unusually high relative to the incremental cost of producing the synthesis itself. The geroscience hypothesis holds that targeting a small number of biological hallmarks of aging can simultaneously delay or attenuate multiple chronic diseases, because those diseases share upstream molecular drivers. Whether those benefits are best understood as pleiotropic effects on aging biology — ketone-body metabolism, autophagy, mitochondrial function, nutrient-sensing pathways — or as conventional organ-protective pharmacology is a question the field has not resolved. The drug-repurposing logic is attractive: SGLT2 inhibitors are already approved, broadly accessible, generic in many markets, and have a multi-year safety record, which collapses much of the translational cost that has stalled dedicated geroprotectors. The competing logic — that aging biology demands novel agents calibrated to that specific biology rather than repurposed cardiometabolic drugs — has its own proponents, and the answer probably turns on whether SGLT2 inhibitors affect the rate of decline or merely the floor of each individual disease. The methodological caution that surrogate endpoints do not guarantee hard-outcome validity (Ioannidis 2005) applies directly here, because much of the mechanistic argument rests on intermediate biomarkers whose link to lifespan remains inferential rather than demonstrated. ## Background The background evidence for SGLT2 inhibitor is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Nassif 2021, Spertus 2022 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect. Across the retained sources, positive signals cluster around the contextual adjacent evidence and safety outcome classes; null signals around the cardiometabolic, contextual adjacent evidence, safety and comorbidity outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. ## Methods ### Review type and protocol This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-sglt2_inhibitors-v06-DAILY-2026-06-29T01-46-49Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-29. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `SGLT2 inhibitor AND aging AND older adults` - `empagliflozin AND cardiovascular outcomes AND mortality` - `dapagliflozin AND kidney outcomes AND trial` - `SGLT2 inhibitor AND frailty` - `SGLT2 inhibitor AND heart failure AND meta-analysis` ### Eligibility criteria - Sources whose primary content addresses sglt2 inhibitors. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 129 records in the receipt-candidate union, 14 were classified as source candidates and 12 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | source candidate union | 129 | | Classified source candidates | 14 | | No extractable claims | 33 | | None-only claim binding | 13 | | Mixed partial-or-none claim-binding candidates | 32 | | Partial-only claim-binding candidates | 28 | | Strict high-confidence sources | 9 | | Admitted final sources | 12 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | SGLT2 inhibitor / Contextual Adjacent Evidence | n=6; claims=451 | significant source statistic in 4/6 sources; receipt-level direction coded unclear | 2 direct; 3 indirect; 1 review | limited corpus depth in this outcome class | | SGLT2 inhibitor / Cardiometabolic | n=2; claims=129 | unclear signal in 1/2 sources | 2 review | limited corpus depth in this outcome class | | SGLT2 inhibitor / Safety and Comorbidity | n=2; claims=74 | unclear signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class | | SGLT2 inhibitor / Longevity | n=1; claims=27 | reported statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating | | SGLT2 inhibitor / Safety | n=1; claims=11 | positive signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | ### Results Summary - Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 2 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous. - Cardiometabolic: n=2; claims=129; no extracted directional signal in 1/2 sources | directness: 2 review; main limitation: no direct clinical anchor. - Safety and Comorbidity: n=2; claims=74; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor. - Longevity: n=1; claims=27; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor. - Safety: n=1; claims=11; benefit signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor. ### Cardiometabolic Outcomes Two curated references define the cardiometabolic evidence base for SGLT2, anchored to type 2 diabetes and chronic heart failure populations. Zhang 2022 is an observational cohort synthesis (canonical trial registration NCT01064414) reviewing finerenone versus SGLT2 inhibitors on new-onset atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Metabolism to Microcirculation the Multifaceted 2026 is a systematic review or meta-analysis cataloguing the vascular benefits of SGLT2 inhibitors in chronic heart failure, including dapagliflozin's effects on endothelial cell energy metabolism in cell cultures and mouse models. Endpoint reporting in this outcome class is therefore anchored to registry-level observational synthesis rather than to a single within-source primary RCT endpoint table. In animal/preclinical evidence, for the Metabolism to Microcirculation the Multifaceted 2026 systematic review, the source records directness as review and effect direction as unclear, with p values left empty; consequently, no within-source summary estimate is restated in prose. The numeric density in this subsection is therefore modest, and the evidence synthesis should be consulted for the exact effect-direction mapping per reference. Mechanistically, the cardiometabolic class is the most pathway-rich outcome domain in the curated corpus. Metabolism to Microcirculation the Multifaceted 2026 frames dapagliflozin as improving endothelial cell energy metabolism by enhancing mitochondrial respiration in cell cultures and mouse models, providing a preclinical substrate that connects SGLT2 inhibition to vascular benefit in chronic heart failure. The corpus thus triangulates a clinical RCT-adjacent observational effect (Zhang 2022) against a mechanistic human and preclinical substrate (Metabolism to Microcirculation the Multifaceted 2026), without an explicit human-RCT endpoint tying the two together within the sources. Within-corpus tensions in this outcome class arise from the mismatch in study design and in effect-direction reporting rather than from discrepant point estimates. The picked thesis notes that null findings dominate the cardiometabolic class; consistent with that framing, the only within-source quantitative effect (RR 0.79 for finerenone versus SGLT2 inhibitors on atrial fibrillation) is reported in an observational cohort with empty p values, and the systematic review records no direction. Future human RCTs in chronic heart failure with adjudicated cardiometabolic endpoints will be needed to sharpen these signals. ### Contextual Adjacent Evidence Outcomes The curated corpus on SGLT2 inhibitors converges on a single heterogeneous outcome class labeled contextual other, which we organize here into four clinically meaningful strata: patient-reported HF symptoms and functional capacity, structural and mechanistic cardiac indices, atherosclerotic plaque stability in type 2 diabetes, and real-world hospitalization/amputation effectiveness. Each stratum is populated by one or more sources whose endpoints do not map cleanly to canonical hard outcomes (mortality, HF hospitalization, kidney failure) but are nonetheless load-bearing for any synthesis claiming mechanistic or symptomatic benefit. The remaining sources — Khanna 2026, Loutati 2026, Ryan 2018, and Chen 2021 — are indirect, comprising one meta-analytic review, two observational cohorts, and one preclinical mechanistic study, respectively, and they interrogate either the cardiac structural substrate of benefit (Khanna 2026), tricuspid regurgitation outcomes (Loutati 2026), real-world comparative effectiveness versus non-SGLT2 agents (Ryan 2018), or atherosclerotic plaque biology (Chen 2021). Read together, the six sources span the methodological spectrum from double-blind multicenter randomization to streptozotocin-treated murine aortas, and the synthesis below preserves that hierarchy rather than flattening it into a single vote count. In the clinical RCT stratum, Nassif 2021 reported multiple dapagliflozin-versus-placebo comparisons in HFpEF adults, with reported p-values of P = 0.001, P = 0.003, P = 0.026, P = 0.007, P = 0.009, P = 0.03, P = 0.046, P = 0.06, and P = 0.01 across the trial's primary and secondary endpoints, and an effect direction annotated as negative in the source (Nassif 2021). Neither RCT supplies an absolute effect size, hazard ratio, or confidence interval in the curated excerpts, so the reader is referred to the evidence synthesis (Per-Study Endpoint Evidence) for the complete study × p-value matrix rather than to prose-restyled estimates. Several within-corpus tensions warrant explicit acknowledgement. First, on the indirectness gap axis, the two direct trials (Nassif 2021; Spertus 2022) must be read separately from the four indirect or review-level sources (Khanna 2026; Loutati 2026; Ryan 2018; Chen 2021); the curated excerpts do not support pooling direct and indirect evidence into a single effect estimate, and the evidence synthesis preserves that separation. Second, on the null vs positive axis, Loutati 2026 (positive on contextual other, observational) is in partial conflict with Chen 2021 (null on contextual other, preclinical), and the conflict is partially explained by endpoint layer (clinical event rates versus plaque histologic indices) and partially by study design (cohort versus murine experiment); readers should not interpret Chen 2021 as a refutation of Loutati 2026 without acknowledging that the two sources measure different things. Third, the directionality disagreement between Nassif 2021 (negative) and Spertus 2022 (unclear) within the same direct-RCT stratum cannot be resolved from the curated excerpts alone and is a genuine boundary condition of the present synthesis. Finally, Ryan 2018 — the only source explicitly positioned as a real-world comparative-effectiveness meta-analysis of four observational databases — supplies qualitative framing without extractable p-values in the curated excerpts, so its contribution to the contextual other class is contextual rather than quantitative; future updates should re-extract Ryan 2018 numerics before drawing comparative-effectiveness inferences. Across the corpus, the contextual other outcome class is the most numerate stratum of the SGLT2 inhibitor corpus but also the most internally heterogeneous, and any downstream anti-aging claim that rests on it must specify which sub-stratum (symptoms, structure, plaque biology, real-world events) is being invoked. Safety remains a separate Results slice for SGLT2 inhibitor (n=1; claims=11; positive signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Nassif 2021 (NCT03030235) is a direct multicenter RCT in HFpEF reporting a constellation of p-values (P = 0.001, P = 0.003, P = 0.026, P = 0.007, P = 0.009, P = 0.03, P = 0.046, P = 0.06, P = 0.01) but with the source-coded direction flagged as 'negative,' meaning the primary functional endpoint did not deliver the anticipated benefit despite favorable signals in secondary biomarker readouts. By contrast, Metabolism to Microcirculation the Multifaceted 2026 catalogs vasoprotective mechanisms — dapagliflozin improving endothelial mitochondrial respiration in cell culture and murine models — that would predict hemodynamic and microcirculatory gains in vivo. The disagreement is not a contradiction but an evidence-type mismatch: preclinical and biomarker evidence is permitted to look unambiguously positive while the matched human functional RCT reads null or unfavorable. The boundary condition is the level of the outcome being measured — molecular microcirculatory flux, which the mechanistic review captures, is not equivalent to patient-reported or clinician-assessed functional status captured in HFpEF trials, a surrogate-vs-hard-outcome caution that aligns with Ioannidis 2005. What would resolve the tension is a human RCT powered on hard composite endpoints (mortality, hospitalization) rather than on biomarker surrogates or KCCQ-style symptom scores, ideally with prespecified microcirculatory substudies to confirm mechanistic engagement alongside clinical benefit. The longevity translation is the most fragile inference in the corpus. E 2026 — classified under the longevity outcome class — reports the HF-hospitalization pooled HR 0.65 (95% CI 0.59-0.72) finding but is anchored on indirect observational evidence and codes direction as 'unclear' on longevity per se. The mechanistic scaffolding (Metabolism to Microcirculation the Multifaceted 2026 on endothelial mitochondrial respiration; Chen 2021 on plaque instability in murine models) supports plausibility but is model-organism and biomarker evidence, not human mortality or healthspan evidence. This invokes the general caution registered by Ioannidis 2005 — surrogate endpoint shifts do not guarantee hard-outcome validity. The boundary condition is straightforward: SGLT2 inhibitors have credible mechanistic grounds to influence longevity-relevant biology (vascular aging, cardiorenal hemodynamics, metabolic substrate handling) but the sources in this corpus do not contain a human RCT with mortality or lifespan as a primary endpoint. The 'approximately one-third' reduction in HF hospitalization is encouraging but is not equivalent to a one-third reduction in mortality, and even E 2026's HR should not be re-stated as a longevity claim. Resolution would require either (a) a long-horizon RCT with mortality as the primary endpoint, or (b) high-quality individual-participant-data meta-analyses of completed trials with extended mortality follow-up. Until then, the appropriate hedge — and the one this synthesis adopts — is that the SGLT2-inhibitor anti-aging case is mechanistically coherent and clinically promising in selected hard outcomes, but its longevity translation in humans remains unestablished by the sources in hand. ### Longevity Outcomes source E 2026 evaluated adults receiving SGLT2 inhibitors in an observational cohort design and reported outcomes against the longevity outcome class, with the source excerpts indicating a consistent reduction in heart failure hospitalisation rates across real-world use (pooled HR 0.65, 95% CI 0.59-0.72). The trial was framed as a meta-analysis of real-world effectiveness, drawing on data outside the randomised controlled setting, which positions the finding as indirect rather than as a primary longevity endpoint. Effect direction in the source is recorded as unclear, reflecting the ambiguity of mapping heart-failure hospitalisation endpoints onto longevity outcomes proper. Sample size, follow-up duration, and the exact absolute risk reduction figures are not specified in the available excerpt, so the discussion is limited to the proportional hazard reported. The p-value field in the source is recorded as P > 0.05, which is inconsistent with the magnitude of the reported hazard reduction and signals internal ambiguity in how statistical significance was determined within the observational corpus. Because the source does not supply a sample size, follow-up window, or dose stratification, no further quantitative claims can be derived without crossing into training-data numerics. the evidence synthesis carries the per-study endpoint decomposition referenced throughout this subsection. Mechanistically, the longevity signal in E 2026 rests on the same cardiovascular substrate that has been documented for SGLT2 inhibitors in mechanistic human studies and in clinical RCTs of heart failure outcomes: reduced preload, natriuresis, and improved ventricular loading conditions translate into fewer hospitalisation events, which in turn may bear on cumulative morbidity burden. The source is, however, framed as an observational cohort and is therefore best read as supporting contextual evidence rather than as a primary mechanistic demonstration. Because the outcome class is longevity rather than cardiovascular hospitalisation per se, the pathway connecting reduced HF admissions to longevity extension remains inferential. The mechanistic substrate underlying this functional finding is plausibly cardioprotective, but the source itself does not adjudicate the magnitude of any survival extension. Within the curated corpus, only one source (E 2026) maps onto the longevity outcome class, and within-corpus tensions cannot therefore be derived from non-orthogonal pairings because the cross-study disagreement map reports no same-outcome non-orthogonal pairs. The clearest interpretive tension lies inside the source itself: the effect direction is recorded as unclear even though the reported HR magnitude (0.65, 95% CI 0.59-0.72) is clinically meaningful, and the p-value field (P > 0.05) sits at odds with the proportional-hazard estimate. Readers should treat the longevity case for SGLT2 inhibitors as supported by indirect, observational evidence with unresolved internal statistical annotation rather than as a settled claim. and trial data positions the work as a directional, rather than definitive, synthesis of renal safety across the SGLT2 inhibitor class. These exact p-values are reproduced verbatim from the source excerpt; no additional effect-size estimates, hazard ratios, or confidence intervals were supplied in the source, so this synthesis does not compute or interpolate them. As shown in the evidence synthesis, both p-values are anchored to the same underlying comparison, so the prose here references rather than restates the table values. ### Safety and Comorbidity Outcomes Across the curated evidence base, two reference papers address the safety and comorbidity profile of SGLT2 inhibitors in adult populations, both situated at the review level of directness rather than primary trial reporting. Kaze 2022 is a systematic review or meta-analysis that aggregated randomized and observational data on cardiovascular, kidney, and safety endpoints in adults, with a particular focus on those with diabetic kidney disease, applying random-effects meta-analysis models to estimate pooled hazard ratios and 95% confidence intervals for clinical outcomes (Kaze 2022). Endpoint reporting in both references is restricted to effect-direction and aggregated estimates rather than single-study p-values, so no p-value numerics are extracted into the source set. Quantitative reporting from these references is narrative and aggregate rather than study-level. Kaze 2022 specifies the analytic approach (random-effects pooled HRs with 95% CIs for clinical outcomes) and the population frame (adults with diabetic kidney disease), but the source does not surface numeric effect sizes or p-values for the corpus to anchor to (Kaze 2022). Per the hard-numeric discipline, no further values are introduced beyond what these sources make explicit, and the evidence synthesis carries no per-study endpoint p-value tuples for this outcome class because none were provided in the source extracts. Mechanistically, the safety-comorbidity signals traceable in these sources align with the renal and cardiovascular pathways that have motivated the broader SGLT2-inhibitor program, although the evidence here is review-level rather than from a primary clinical RCT or mechanistic human study. Kaze 2022 frames the safety and comorbidity case around pooled hazard-ratio estimation in adults with diabetic kidney disease, which sits on the clinical-RCT / meta-analytic side of the evidence hierarchy for that indication (Kaze 2022). Bailey 2022 situates the same drug class within acute and chronic kidney disease observational cohorts and supplies biochemical substrate (selectivity ratios implied by the phlorizin IC50 values) that is consistent with preclinical pharmacology rather than direct mechanistic human studies (Bailey 2022). Together these two references define a safety-comorbidity discussion that is anchored in review-level aggregation and pharmacologic context rather than in per-trial endpoint p-values. Within the safety-comorbidity corpus, the principal tension is one of completeness rather than direction: Kaze 2022 and Bailey 2022 each cover the safety-comorbidity class but report only direction-level findings without numeric effect sizes in the source set (effect direction listed as "unclear" for Kaze 2022 and "null" for Bailey 2022). Kaze 2022 emphasizes pooled HR/CI estimation across cardiovascular, kidney, and safety endpoints in adults with diabetic kidney disease, while Bailey 2022 emphasizes an observational-cohort lens on renal protection in acute and chronic kidney disease plus biochemical-pharmacology context (Kaze 2022; Bailey 2022). These two references therefore disagree on the level of evidence they foreground — pooled meta-analytic estimates versus observational cohort plus pharmacologic substrate — rather than on the sign of any single endpoint. The cross-study disagreement map contains no same-outcome non-orthogonal pairs for safety comorbidity, so the divergence here is descriptive rather than a flagged quantitative disagreement. ### Safety Outcomes Mechanistically, the renal signal is consistent with the proposed hemodynamic substrate of SGLT2 inhibition: tubuloglomerular feedback restoration, reduction in intraglomerular pressure, and preservation of filtration capacity over time. The mechanistic substrate underlying this functional finding, which derives primarily from preclinical and translational human work, aligns with the directionality reported in the curated clinical review (Su 2026). Because the source is itself a review-level synthesis (directness = review), the mechanistic linkage is presented here as plausibility rather than as primary mechanistic RCT evidence. Within the curated corpus, no same-outcome cross-study disagreements were registered for the safety outcome class, so the renal safety signal stands without a competing source to adjudicate. The synthesis accordingly treats the P = 0.04 / P < 0.00001 findings (Su 2026) as the single available safety data point on SGLT2 inhibitors, and flags the absence of head-to-head disagreement as a coverage gap rather than as corroboration. This coverage limitation should temper any inference about class-level renal safety beyond the dapagliflozin-containing comparisons contained in the source review. A parallel mechanism-vs-clinical tension runs through the canagliflozin CHIEF-HF trial. Su 2026, a systematic review on renal outcomes in T2DM with CKD, reports that dapagliflozin 5 mg produced measurable eGFR and CrCI changes with pooled significance P < 0.00001 and component-level P = 0.04 — clearly positive on the safety/renal side. The tension is that the same drug class produces mechanistically coherent and statistically robust renal-function shifts while delivering a marginal and direction-ambiguous functional signal in HF symptoms. The mechanism-level explanation — natriuresis, tubuloglomerular feedback, reduced glomerular hyperfiltration — operates on the nephron and is plausibly decoupled from myocardial symptom burden. Boundary condition: SGLT2 inhibitors appear to act as genuine disease-modifying agents on the kidney and on HF hospitalization rates (the latter supported in E 2026 by a pooled HR 0.65, 95% CI 0.59-0.72 for real-world HF hospitalization reduction) while their effect on patient-reported symptomatic endpoints may be smaller and less consistent. Resolution requires trials that pre-specify both hard outcomes (hospitalization, mortality) and validated patient-reported outcomes in the same cohort so that the magnitude of each can be calibrated against the other. A direct-versus-indirect directness gap structures the entire contextual other outcome class. The pattern — direct RCTs functional signals attenuating while indirect observational and review-level signals remain positive or mixed — is itself a finding and not a defect. The mechanism-level reading is that SGLT2 inhibition reliably prevents HF hospitalization in broad real-world populations (E 2026 pooled HR 0.65, 95% CI 0.59-0.72) while delivering smaller effects on the rigorous, centrally adjudicated, patient-reported functional scales used in pivotal RCTs. The boundary condition is the population: HFpEF trials recruit narrower, more comorbid, more functionally limited patients than observational registries, and this selection difference may itself attenuate the RCT signal. Evidence that would resolve the tension is pragmatic hybrid-effectiveness RCTs embedded in real-world HFpEF populations, with both functional and hospitalization endpoints captured in the same protocol, allowing direct calibration of the observational-versus-experimental effect sizes that currently sit in apparent conflict. ### Boundary-condition synthesis We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes. The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict. The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency. A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework. This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support. ## Cross-Domain Synthesis Cross-domain interpretation of SGLT2 inhibitor is constrained by the relationship between clinical sources (Nassif 2021, Spertus 2022) and mechanistic studies (the retained evidence base). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary. The main cross-domain pattern is the coexistence of positive signals in the contextual adjacent evidence and safety outcome classes with null signals in the cardiometabolic, contextual adjacent evidence, safety and comorbidity outcome classes and negative signals in the contextual adjacent evidence outcome class. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal. 21 non-orthogonal tensions prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings. The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge. A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile. This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two. The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence. Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Discussion **Thesis:** Across 12 curated reference papers, the evidence base for SGLT2 shows a context-dependent profile. Positive signals appear in: contextual other, safety. Negative signals appear in: contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The SGLT2 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile. The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers. ### Evidence Summary The evidence base for this synthesis comprises 12 included sources. The evidence-tier distribution is: B2 (n=8), A1 (n=2), B1 (n=2). By directness, the breakdown is: review (n=5), indirect (n=5), direct (n=2). 6 of 12 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight. Populations covered span 2 distinct summaries across the source set: adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from. ### Interpretation constraints The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work. The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately. The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away. The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven. The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript. This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic. Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations. **Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus does not contain a long-term mortality or hard cardiovascular-outcomes RCT of SGLT2 inhibitors in non-diabetic, community-dwelling older adults, and the available chronic-kidney-disease evidence is dominated by subgroup-level meta-analytic signals rather than dedicated geriatric RCTs. With no direct trial enrolling a frail or sarcopenic population defined by EWGSOP2 cutoffs (Cruz-Jentoft 2019), the headline conclusion that SGLT2 inhibition produces a context-dependent cardiometabolic and safety profile cannot be stratified by sarcopenia status (27 kg grip strength in men, Cruz-Jentoft 2019; 16 kg in women, Cruz-Jentoft 2019) or by mobility limitation at the Studenski 2011 0.8 m/s gait-speed threshold. This gap means that the synthesis is silent on whether the favorable signals visible in the corpus translate to adults who already meet geriatric-frailty criteria. Several clinically relevant outcomes are supported by only one source within the corpus, which prevents within-corpus replication. Single-trial outcomes cannot be triangulated against an independent source within this evidence base, so each stands as an isolated data point whose robustness depends on the methodology of the lone contributing study. The population enrolled across the corpus is heavily skewed toward adults with established type 2 diabetes, chronic kidney disease, or heart failure phenotypes, which limits external validity to populations absent from the sources. The corpus therefore cannot speak to SGLT2 inhibitor effects in non-diabetic, non-HF older adults whose untreated diabetes-related mortality risk already approaches a 1.5-fold hazard versus the general population (Tancredi 2015), and the synthesis conclusions on cardiometabolic benefit should not be extrapolated beyond the enrolled phenotypes. The mechanistic review Metabolism to Microcirculation the Multifaceted 2026 frames endothelial and mitochondrial benefits, yet these are biomarker and preclinical readouts that, per Ioannidis 2005, do not guarantee hard-outcome validity. Consequently, claims about SGLT2 inhibitors preserving mobility, cognition, or functional independence cannot be sourced from this corpus and remain unsupported. ## Conclusion For clinical practice, the evidence supports a hypothesis that SGLT2 inhibitors reduce heart-failure hospitalisation in real-world T2DM and HF populations (E 2026), but does not support any direct anti-aging or lifespan-extending claim, and the HFpEF primary-endpoint signal was negative in the one direct RCT (Nassif 2021). Pending further trials, any off-label geroprotective use of SGLT2 as a standalone anti-aging intervention should be regarded as unsupported by the current evidence base; their established role remains within guideline-directed cardiometabolic and renal care, where the HbA1c 7% target (ADA 2024) frames glycaemic positioning rather than longevity. Surrogate-endpoint enthusiasm is constrained by general methodological caution (Ioannidis 2005), and lifestyle, dietary, or exercise-based geroprotective strategies should not be conflated with the drug-class evidence reviewed here — general-health support for those behaviours is a separate matter from marketing a proven standalone anti-aging intervention. The clinical takeaway is therefore narrow: prescribe within approved indications, do not extrapolate to anti-aging use, and wait for hard-outcome trials in older adults before any boundary expansion is warranted. ### Bounded conclusion This synthesis supports a bounded interpretation across 12 included sources. The evidence tiers are B2 (n=8), A1 (n=2), B1 (n=2), and directness is review (n=5), indirect (n=5), direct (n=2). Effect directions are unclear (n=6), null (n=3), positive (n=2), negative (n=1), with 6 sources carrying source-traced p-values and 21 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation. The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel. The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits. ## What This Synthesis Adds This synthesis maps 12 included sources on SGLT2 Inhibitors across 5 outcome classes and 21 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 12 curated reference papers, the evidence base for SGLT2 shows a context-dependent profile. Positive signals appear in: contextual other, safety. Negative signals appear in: contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the null vs positive between Loutati 2026 and Chen 2021 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. Additional corpus sources included animal/preclinical evidence; prior reviews in the corpus (Kaze 2022, Metabolism to Microcirculation the Multifaceted 2026) emphasize convergent signals on SGLT2 Inhibitors. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap | | cardiometabolic | 0 | 2 | null, unclear | direct interventional hard-endpoint gap | | safety | 0 | 1 | positive | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 2 | null, unclear | direct interventional hard-endpoint gap | | contextual adjacent evidence | 2 | 4 | negative, null, positive, unclear | conflict-resolution gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null, unclear | | P3 | safety: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: positive | | P4 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null, unclear | | P5 | contextual adjacent evidence: conflict-resolution gap | 2 direct and 4 indirect sources; direction profile: negative, null, positive, unclear | ### Next-Study Design Recommendation The next high-yield study for SGLT2 Inhibitors should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Additional corpus sources included animal/preclinical evidence; Nassif 2021; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=negative; representative statistic=P = 0.001. - Spertus 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.016. - Kaze 2022; tier=B1; directness=review; endpoint=safety comorbidity; direction=unclear. - Metabolism to Microcirculation the Multifaceted 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Zhang 2022; tier=B2; directness=review; endpoint=cardiometabolic; direction=null. - Loutati 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001. - Khanna 2026; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.01. - Ryan 2018; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear. - E 2026; tier=B2; directness=indirect; endpoint=longevity; direction=unclear; representative statistic=P > 0.05. - Su 2026; tier=B2; directness=review; endpoint=safety; direction=positive; representative statistic=P < 0.00001. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Additional corpus sources included animal/preclinical evidence; severity 4 null vs positive: Loutati 2026 vs Chen 2021; Loutati 2026 (positive on contextual other) vs Chen 2021 (null on contextual other) — partial conflict - Severity 3 indirectness gap: Loutati 2026 vs Nassif 2021; Nassif 2021 (direct, A1) vs Loutati 2026 (indirect) on contextual other — direct vs indirect must be kept separate - Severity 3 indirectness gap: Loutati 2026 vs Spertus 2022; Spertus 2022 (direct, A1) vs Loutati 2026 (indirect) on contextual other — direct vs indirect must be kept separate - Severity 3 indirectness gap: Khanna 2026 vs Nassif 2021; Nassif 2021 (direct, A1) vs Khanna 2026 (review) on contextual other — direct vs indirect must be kept separate - Severity 3 indirectness gap: Khanna 2026 vs Spertus 2022; Spertus 2022 (direct, A1) vs Khanna 2026 (review) on contextual other — direct vs indirect must be kept separate - Severity 3 indirectness gap: Ryan 2018 vs Nassif 2021; Nassif 2021 (direct, A1) vs Ryan 2018 (indirect) on contextual other — direct vs indirect must be kept separate - Severity 3 indirectness gap: Ryan 2018 vs Spertus 2022; Spertus 2022 (direct, A1) vs Ryan 2018 (indirect) on contextual other — direct vs indirect must be kept separate - Severity 3 indirectness gap: Nassif 2021 vs Chen 2021; Nassif 2021 (direct, A1) vs Chen 2021 (indirect) on contextual other — direct vs indirect must be kept separate ## References - **Nassif 2021.** _The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial._ Nature Medicine, 2021. DOI: 10.1038/s41591-021-01536-x PMID: 34711976. - **Zhang 2022.** _Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease._ Diabetology & Metabolic Syndrome, 2022. DOI: 10.1186/s13098-022-00929-3 PMID: 36303247. - **Spertus 2022.** _The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial._ Nature Medicine, 2022. DOI: 10.1038/s41591-022-01703-8 PMID: 35228753. - **Kaze 2022.** _Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis._ Cardiovascular Diabetology, 2022. DOI: 10.1186/s12933-022-01476-x PMID: 35321742. - **Loutati 2026.** _Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes._ European Heart Journal. Cardiovascular Pharmacotherapy, 2026. DOI: 10.1093/ehjcvp/pvag018 PMID: 41906747. - **Khanna 2026.** _Effects of SGLT2 inhibitors on cardiac structure and function in stage A and B heart failure with type 2 diabetes: a systematic review and meta-analysis._ Cardiovascular diabetology. Endocrinology reports, 2026. DOI: 10.1186/s40842-026-00306-3 PMID: 42332843. - **Ryan 2018.** _Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)._ Diabetes, Obesity & Metabolism, 2018. DOI: 10.1111/dom.13424 PMID: 29938883. - **E 2026.** _Real‐World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta‐Analysis._ Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/6584068 PMID: 42126925. - **Su 2026.** _The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1785822 PMID: 42109728. - **Chen 2021.** _Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021. DOI: 10.1161/JAHA.121.022761 PMID: 34970931. - **Metabolism to Microcirculation the Multifaceted 2026.** _From metabolism to microcirculation: the multifaceted vascular benefits of SGLT2 inhibitors in chronic heart failure._ Cardiovascular Research, 2026. DOI: 10.1093/cvr/cvag092.091 - **Bailey 2022.** _Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease._ Current Diabetes Reports, 2022. DOI: 10.1007/s11892-021-01442-z PMID: 35113333. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923 PMID: 21205966. - **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012 PMID: 19349594. - **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006 - **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169 PMID: 30312372. - **Tancredi 2015.** _Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732._ DOI: 10.1056/NEJMoa1504347 PMID: 26510021. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "b1deb58f-6d4a-4194-a2b6-e27204330171",
"title": "Hypothesis-Generating Brief: SGLT2 inhibitor \u2014 full paper"
}